Clinical trials
Other Solid Tumors clinical trials
Below are recruiting other solid tumors clinical trials, each written for real people, not researchers. We’re tracking 1,667 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04723810RecruitingPhase 1/Phase 2
Test a glowing scan to help surgeons find tumor tissue
This early-stage study tests an intraoperative imaging approach called “TumorGlow” to help surgeons better identify tumor tissue during surgery. It may help improve the completeness of tumor removal and reduce the chance of recurrence in certain patients.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04764357Recruiting
Scalp cooling to help prevent chemotherapy-related hair loss in kids
This study looks at whether “cold cap” scalp cooling can help prevent or reduce hair loss in children getting chemotherapy. It’s aimed at kids treated with certain chemotherapy medicines and who may be at risk for losing their hair.
Memphis, TennesseeAges 7 years+ - NCT04762862Enrolling by invitation
Testing gene-guided cancer treatment changes in advanced tumors
This trial studies whether measuring changes in your tumor’s genes (from pangenomic quantitative testing) can help guide cancer treatment when standard cures aren’t available. It may help doctors choose therapies based on what your tumor shows.
NiceAges Any age - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Scottsdale, ArizonaAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Birmingham, AlabamaAges 18 years+ - NCT04665388Recruiting
Mapping immune responses in people with certain virus-related cancers
This study collects blood and/or tumor-related samples to map how your immune system recognizes cancer. It aims to better understand immune targets and immune cell types, which may help guide future cancer treatments for certain virus-related cancers.
Toronto, OntarioAges 18 years+ - NCT04516447RecruitingPhase 1
Testing a new drug for advanced ovarian cancer
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
Aurora, ColoradoAges 18 years+ - NCT04389281RecruitingPhase 1
X-ray light-activated therapy for hard-to-treat skin tumors
This early-phase study tests an X-ray–activated medicine that is delivered directly into selected tumors to help control cancer that has not responded to standard treatments. If the injected area can be treated safely, it may shrink or slow the tumor and improve local control.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04390737RecruitingPhase 1/Phase 2
Study drug HH2853 for hard-to-treat lymphoma and solid cancers
This Phase 1/2 trial tests the safety and early effectiveness of HH2853 in people whose cancer has come back or did not respond to prior treatment. It may help shrink tumors and guide future treatment for specific cancer types and genetic changes.
Phoenix, ArizonaAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
La Jolla, CaliforniaAges 18 years+ - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT04260269Enrolling by invitation
Testing a switch to a different chemotherapy type after heart side effects
This study looks at whether people with solid tumors who develop heart-related side effects during a fluoropyrimidine chemotherapy can safely switch to a different fluoropyrimidine. It aims to see if the new option is feasible to use again when the first one caused cardiotoxicity.
OdenseAges 18 years+ - NCT04243720Recruiting
Study of immune resistance after immunotherapy
This trial studies why some solid cancers stop responding to immune-based drugs (like anti–PD-1/PD-L1) and what can be done next. You may be eligible if your cancer has progressed after immunotherapy and you can safely undergo a tumor needle biopsy.
Toronto, OntarioAges 18 years+ - NCT04142437Recruiting
Tracking how larotrectinib works for NTRK fusion cancers in routine care
This study follows people with cancers that have an NTRK gene fusion to learn how safe and effective larotrectinib is during everyday treatment. It may help confirm whether this medicine works well in real-world patients and side effects stay manageable.
Mesa, ArizonaAges Any age - NCT03715933RecruitingPhase 1
Test drug INBRX-109 for advanced or metastatic solid tumors
This Phase 1 trial tests INBRX-109, a cancer-targeting drug, in people whose solid cancers are locally advanced or spread to other parts of the body. Because it’s Phase 1, the main goal is to see whether it’s safe and how well it can work for different tumor types that meet specific requirements.
Scottsdale, ArizonaAges 12–85 - NCT03340506RecruitingPhase 4
Follow-on treatment study for dabrafenib and trametinib
This study lets people who finished a prior dabrafenib/trametinib trial (sponsored by Novartis or former GSK) continue those medicines if the study doctor thinks it will help. It mainly focuses on ongoing treatment benefit rather than testing a new drug.
Scottsdale, ArizonaAges 18–100 - NCT03297606RecruitingPhase 2
Match your tumor test to a targeted cancer drug
This trial studies whether giving a targeted cancer medicine based on tumor genetic/protein test results can help people with advanced, incurable cancers live longer. You may be eligible if your cancer has a “potentially actionable” change on testing and you meet health and follow-up requirements.
Edmonton, AlbertaAges 18 years+ - NCT03310879RecruitingPhase 2
Abemaciclib for advanced tumors with cyclin or CDK4/6 gene changes
This Phase 2 study tests abemaciclib, a targeted cancer medicine, in people with advanced solid tumors that have specific gene changes related to cyclin D or CDK4/6. The goal is to see how well it controls tumors when standard treatments don’t work or aren’t available.
Boston, MassachusettsAges 18 years+ - NCT03093909RecruitingPhase 1
Breathing treatment with gemcitabine for lung cancer spread
This early-stage trial studies an inhaled (aerosol) form of gemcitabine to treat solid tumors that have spread to the lungs. It aims to see whether this lung-focused treatment is safe and how well it might work when standard curative options are not available.
Houston, TexasAges 12–50 - NCT02806388Recruiting
Molecular testing to match you to the right cancer trial
This trial uses a tissue sample from your tumor to look for specific molecular changes, then helps match you to available clinical trials. It may help by directing treatment research toward tumors most likely to benefit.
SingaporeAges 12 years+ - NCT02315599Enrolling by invitation
Follow-up for delayed side effects after gene-cell therapy
This study checks people for delayed side effects after receiving gene-based cell therapy from the NIH. It helps doctors learn what problems may happen later and how to monitor them safely.
Bethesda, MarylandAges 1–99 - NCT02534649Recruiting
Drug-matching trial for adults with cancer DNA changes
This trial looks for the specific DNA or tumor changes in your cancer and then matches you to a targeted drug plan. It’s meant for people with early cancer that has not already been treated in this study.
BayonneAges 18 years+ - NCT02457962Recruiting
Registry study of outcomes from Mayo radiation treatments
This study collects information about how patients do after radiation treatment and stores some biological samples for future research. It includes people treated at Mayo Clinic Rochester for a cancer-focused (curative) course of radiation.
Rochester, MinnesotaAges Any age - NCT02421380Recruiting
Tests how repeatable a special MRI scan is for tumors
This study checks whether a specialized MRI using injected “hyperpolarized pyruvate” gives consistent tumor images when repeated. It may help future patients by improving how reliably this scan can measure tumors.
Montvale, New JerseyAges 21–90
Hear when a new Other Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other solid tumors?
- Yes. Clin2 currently lists 1,667 recruiting other solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.